Pennsylvania is currently home to 3307 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Radiotherapy with Cisplatin Vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
NCT02128906
Recruiting
The goal of this clinical research study is to learn which chemotherapy combination may be more effective in treating locally advanced head and neck squamous cell carcinoma (HNSCC). The side effects of these combinations will also be studied. This study treatment consists of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy. For study chemotherapy, patients will be randomized between cisplatin or the combination of docetaxel and cetuximab. Subjects will be stratified depe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: UPMC Hillman Cancer Center - Radiation Oncology, Pittsburgh, Pennsylvania
Conditions: Squamous Cell Carcinoma
Register for Updates
Safety and Efficacy of FETO in CDH: a Phase III Trial
NCT06884423
Recruiting
Congenital diaphragmatic hernia (CDH) is a birth defect characterized by the development of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs from growing and developing normally. In severe cases, CDH can lead to serious disease and death at birth. For these babies, treatment before birth may allow the lungs to grow enough before birth so t... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Register for Updates
Maximizing Energy and Reducing Fatigue in Breast Cancer Survivors
NCT06879522
Recruiting
This study is testing a program called Maximizing Energy to see if it can help women who have finished breast cancer treatment manage their fatigue. The study has two main goals: 1. Check if the program can be successfully delivered - Researchers will see if women are willing to join and stay in the study, if they follow the program, and if they find it helpful. 2. See if the program works - Researchers will compare Maximizing Energy to a general health education program to see which one helps... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Breast Cancer Survivor, Cancer Related Fatigue
Register for Updates
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
NCT06831149
Recruiting
Investigators performing this research want to look at the use of a special imaging process during a specific throat surgery. Using this imaging may help to lower a common complication that called a pharyngocutaneous fistula (PCF). A PCF is a leak in the tube in the throat that helps with breathing and digesting food. The imaging is called the SPY Fluorescence System. This system can identify tissue that is not receiving enough blood. The SPY Fluorescence System uses a special dye, called Indoc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: UPMC, Pittsburgh, Pennsylvania
Conditions: Squamous Cell Carcinoma, Pharyngocutaneous Fistula
Register for Updates
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462
Recruiting
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/24/2025
Locations: Research Site, Clairton, Pennsylvania
Conditions: Ophthalmic Safety in Patients With Breast Cancer
Register for Updates
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647
Recruiting
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/24/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Register for Updates
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
NCT06721689
Recruiting
The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). The phase 2 primary objective is to estimate the objective response rate (ORR) in children with refractory, progressive and relapsed NBL and rhabdomyosarcoma (RMS) treated with the RP2D of PEEL-224 in combination with vincristine and temozolomide.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
03/24/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma
Register for Updates
Intralesional Injection of STS in Treatment of Calcinosis
NCT06672822
Recruiting
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: UPMC Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania
Conditions: Systemic Sclerosis (SSc), Dermatomyositis, Mixed Connective Tissue Disease (MCTD), Calcinosis
Register for Updates
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
NCT06599619
Recruiting
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Melanoma
Register for Updates
Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs (OPTIMA)
NCT06532890
Recruiting
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/24/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Cardiac Failure, Graft Rejection
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: Hershey Medical Center Pennsylvania State University, Hershey, Pennsylvania
Conditions: Cystic Fibrosis
Register for Updates
EchoTip AcuCore Post-Market Clinical Study
NCT06358001
Recruiting
The purpose of collecting this data is to continue to learn more about the EchoTip AcuCore and the device's ability to produce the desired favorable effect and if there are any undesired outcomes that may be related to the EchoTip AcuCore.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Geisinger Medical Center, Danville, Pennsylvania
Conditions: Adenocarcinoma, Neuroendocrine Tumors, Hepatocellular Carcinoma, Cholangiocarcinoma, Malignant Lymphoma, Metastasis, Chronic Pancreatitis, Autoimmune Pancreatitis
Register for Updates